Key Points This is a breast cancer treatment, Revtorpyk. It was approved by the FDA in July. 10 stocks we like better than Celcuity › On a generally forgettable Wednesday for the stock market, with many titles dropping in value, Celcuity (NASDAQ: CELC) stood out by posting a gain. Investors bought into the company, which is moving from the clinical to the commercial stage with the launch of its first regulator-approved product. Celcuity's stock closed 2.8% higher, on a day when the S&P 500 index slid by 0.3%. The inaugural commercial launch Celcuity, a biotech focused on cancer treatments, announced that its Revtorpyk is now commercially available for eligible patients in the U.S.
Головну думку ми показуємо публічно. Створіть безкоштовний акаунт, щоб читати повну статтю, зберігати її, обговорювати та поєднувати з ринковим і OSINT-контекстом.